Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn's disease

Inflammatory Bowel Diseases

Volumn 11, Issue 2, 2005, Pages 126-132

  Homann, Nils ^a   Klarmann, Ute ^b   Fellermann, Klaus ^a   Brüning, Andreas ^a   Klingenberg Nofts, Rolf ^a   Witthöft, Thomas ^b   Stange, Eduard F ^a   Ludwig, Diether ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Azathioprine; Doppler ultrasound; Inflammatory bowel disease; Prognosis; Splanchnic hemodynamics

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; MERCAPTOPURINE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOPPLER ECHOGRAPHY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; INFERIOR MESENTERIC ARTERY; MAJOR CLINICAL STUDY; MALE; MESENTERY BLOOD FLOW; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUPERIOR MESENTERIC ARTERY; ULCERATIVE COLITIS; BLOOD FLOW; DOPPLER FLOWMETRY; ECHOGRAPHY; HOSPITALIZATION; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MESENTERIC ARTERY, INFERIOR; MESENTERIC ARTERY, SUPERIOR; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER;

EID: 18244403785     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200502000-00005     Document Type: Article

References (38)

1. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30:699-706.
2. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled doses-ranging study. Gastroenterology. 1996;110:45-51.
3. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission in Crohn's disease. Cochrane Database Syst Rev (database online). Issue 4, 2001.
4. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission in Crohn's disease. Cochrane Database Syst Rev (database online). Issue 4, 2001.
5. Present DH, Korelitz BI, Wisch JL, et al. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-987.
6. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
7. Arnott ID, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther. 2002;16:857-867.
8. Brignola C, Campieri M, Bazzocchi G, et al. A laboratory index for predicting relapse in asymptotic patients with Crohn's disease. Gastroenterology. 1986;91:1490-1494.
9. Wyatt J, Vogelsang H, Hübl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet. 1993;341:1437-1439.
10. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease. Lancet. 1999;353:459-461.
11. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991;32:174-178.
12. Ludwig D, Wiener S, Brüning A, et al. Mesenteric blood flow is related to disease activity and risk of relapse in Crohn's disease: a prospective follow-up study. Am J Gastroenterol. 1999;94:2942-2950.
13. Ludwig D, Wiener S, Brüning A, et al. Mesenteric blood flow is related to disease activity and risk of relapse in ulcerative colitis: a prospective follow-up study. Gut. 1999;45:546-552.
14. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. BMJ. 1955;2:1041-1048.
15. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
16. Taylor KJW, Holland S. Doppler ultrasound: Part1. Basic principles, instrumentation, and pitfalls. Radiology. 1990;174:297-307.
17. Bolondi L, Gaiani S, Barbara L. Accuracy and reproducibility of portal flow measurement by Doppler US. J Hepatol. 1991;13:269-273.
18. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med. 1995;123:132-142.
19. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. BMJ. 1982;284:1291-1292.
20. Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of ulcerative colitis. Gastroenterology. 1975;69:96-99.
21. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-678.
22. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20-22.
23. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut .2002;50: 485-489.
24. Dubinsky MC, Lamothe S, Yang HJ, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
25. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904-915.
26. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-362.
27. Alstead EM, Ritchie RK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1990;99: 443-446.
28. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343: 1249-1252.
29. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence of Crohn's disease. Gastroenterology. 1994;106:643-648.
30. Yamamoto T, Allan RN, Keighly MR. Smoking is a predictive factor for outcome after colectomy and ileorectal anastomosis in patients with Crohn's colitis. Br J Surg. 1999;86:1069-1070.
31. Lorenz-Meyer H, Malchow H, Miller B, et al. European Cooperative Crohn's disease study (ECCDS): colonoscopy. Digestion. 1985;31:109-119.
32. Tibble J, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
33. Hulten L, Lindhagen J, Lundgren O, et al. Regional intestinal blood flow in ulcerative colitis and Crohn's disease. Gastroenterology. 1977;72:388-396.
34. Brahme F, Lindström C. A comparative radiographic and pathological study of intestinal vaso-architecture in Crohn's disease and in ulcerative colitis. Gut. 1970;11:928-940.
35. Heyne R, Rickes S, Bock P, et al. Non-invasive evaluation of activity in inflammatory bowel disease. Z Gastroenterol. 2002;40:171-175.
36. Hatoum O, Binion D, Otterson M, et al. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology. 2003;125:58-69.
37. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology. 1997;112:1475-1481.
38. Thjodleifsson B, Sigthorsson G, Cariglia N, et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology. 2003;124:1728-1737.